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S A R A H  M C G L A S S O N  &  D A V I D  H U N T 
Lupus is a complex autoimmune disease that can affect almost any organ in the body1. Brain dysfunction develops in 
many people with the disease, but the molecu-
lar and cellular basis for this aspect of the con-
dition are poorly understood, and there are 
no therapies that target it. In a paper online in 
Nature, Bialas et al.2 provide insight into how 
brain disease can occur in mouse models of 
lupus, and bring a potential therapeutic target 
into focus. 
Type I interferon proteins and their 
receptor are part of a pathway that has a pivotal 
role in the immune response against viral 
infection. Compared with healthy individu-
als, people who have an impaired type I inter-
feron response can be prone to infections, 
whereas individuals who have an overactive 
response might have autoimmune disease or 
organ damage associated with inflammation3,4. 
Abnormal activation of the type I interferon 
response is observed in most people with 
lupus, and a clinical study5 found that inter-
feron-related gene expression correlates with 
specific disease features.
Bialas and colleagues investigated 
previously established mouse models of lupus 
in which there is activation of the type I inter-
feron response6. The authors observed that 
such mice show significant neurological defi-
cits, including poor performance on cognitive 
and behavioural tasks compared with wild-
type animals. However, treating the model 
mice with an antibody that blocks signalling 
through the type I interferon receptor prevents 
these neurological symptoms. 
The authors sought to determine which cells 
might be responsible for this phenomenon. In 
many diseases associated with neuroinflam-
mation, immune cells enter the brain. How-
ever, Bialas et al. found no evidence of such 
infiltration in the brains of the model mice. 
This finding indicates that the cells causing 
neurological damage might originate in the 
brain itself. 
Microglia, the resident immune cells of 
the brain, were considered a prime suspect. 
These cells perform many immunological 
roles, including the active surveillance of their 
environment, and through a process called 
engulfment they can ingest cellular material. 
Inflammation and the presence of cellular 
damage can stimulate microglia to adopt an 
activated state associated with an increase in 
the activity of immune functions, including 
engulfment. The authors found that micro-
glia were in an activated state throughout the 
brains of the model mice, and were responding 
to signalling by type I interferon. 
Using the model mice, Bialas and colleagues 
purified microglial cells and sequenced the 
cellular RNA. Relative to the expression 
patterns observed in wild-type mice, the 
model mice showed upregulation of a broad 
set of interferon-dependent genes, including 
those involved in pathways associated with 
environmental sensing and the engulfment 
of cellular mater ial. In a series of elegant 
experiments, the authors demonstrated an 
association between the observed microglial 
activation and an increased engulfment of neu-
ronal material, particularly of mater ial from 
synapses, which form the junctions between 
two neurons. The use of electron microscope 
imaging enabled the authors to catch microglia 
in the act of synaptic ingestion. 
The number, or density, of synapses was 
found to be decreased in the brains of the 
lupus-model mice, when compared with the 
synaptic density in wild-type mice (Fig. 1). 
These abnormalities could be prevented by 
blocking interferon signalling. Although 
determining whether this mechanism causes 
disease in humans remains a challenge for the 
future, the authors do show evidence of wide-
spread activation of an interferon response in 
microglia and other cell types in the brains of 
people with lupus. Perhaps, in addition to the 
microglia-mediated mechanisms seen in the 
mouse models, humans have other cellular 
targets through which interferon can cause 
brain disease.
These findings have implications for under-
standing core neurobiological processes, as 
well as offering insights of clinical relevance. 
Synaptic pruning by microglial cells was 
originally described as a mechanism that 
helps to sculpt neuronal circuits in the devel-
oping brain7. Subsequent discoveries have 
implicated synaptic pruning as a pathological 
mechanism associated with the early stages 
of some neuro degenerative diseases8. The 
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Figure 1 | Synaptic pruning in autoimmunity. a, In healthy, wild-type animals, resident immune cells 
in the brain known as microglia are usually in a resting state as they patrol the areas around neuronal 
cells and the cellular regions that form synaptic connections. These animals express a low level of 
interferon proteins, which are key regulators of an immune response. b, Bialas et al.2 investigated the 
brain inflammation that can occur as a feature of an autoimmune disease called lupus. The authors used 
previously established6 mouse strains that provide models for studying the disease. These animals have a 
higher level of interferon than do wild-type animals. Bialas and colleagues observed that the microglial 
cells in the model mice adopted an activated state that involved activation of immune functions, including 
the ingestion of cellular material through a process known as engulfment. Using image analysis, the 
authors observed that the activated microglial cells ingested synaptic material from neurons, resulting in 
a reduced synaptic density compared with that of wild-type animals. This change to the synapses could be 
prevented by blocking activation of the interferon pathway (not shown). 
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finding that inflammatory factors such as type I 
interferon can modulate neuronal connec-
tivity will doubtless provoke further debate 
surrounding the expanding list of poten-
tial roles for microglial-mediated synaptic 
pruning in brain health and disease. 
This study adds to the growing scien-
tific rationale for classifying lupus brain 
disease according to the molecular mecha-
nism involved5. This is because it is becoming 
increasingly clear that neurological disease in 
lupus is heterogeneous and can be driven by 
distinct molecular mechanisms. For exam-
ple, some people with lupus develop brain 
disease associated with antibodies that bind 
to proteins expressed on the surface of neu-
ronal cells9, whereas the work by Bialas and 
colleagues adds to an increasing body of evi-
dence pointing to type I interferon as having a 
neurotoxic role3,4,10. Clinical trials of targeted 
therapies are much needed for lupus-associ-
ated neurological disease. The ability to group 
patients according to the molecular mecha-
nisms that drive their disease should facili-
tate such studies and maximize the chance of 
treatment success. 
The tools for studying the therapeutic 
modulation of type I interferon signalling 
in people with lupus continue to increase in 
precision11. Consideration should be given 
to the most effective strategy for modulating 
this pathway in the human brain, because 
the blood–brain barrier poses particular 
challenges for the access of drug treatments. 
Moreover, therapeutic blockade of type I 
interferon signalling in the brain is not 
without potential risks, given the pivotal role of 
this pathway in host defence and the need for a 
basal level of interferon signalling to maintain 
neuronal health12. 
Bialas and colleagues’ work identifies an 
intriguing and previously unknown cause of 
brain damage in mouse models of lupus. But 
perhaps more importantly, it provides a timely 
impetus to consider targeted clinical studies 
that tackle the often-neglected problem of 
brain disease in people with lupus. ■
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